Protease-activated receptors in cancer: A systematic review

被引:43
作者
Han, Na [1 ,2 ]
Jin, Ketao [3 ,4 ]
He, Kuifeng [3 ]
Cao, Jiang [1 ,2 ,5 ]
Teng, Lisong [3 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Inst Clin Med, Hangzhou 310016, Zhejiang, Peoples R China
[2] Key Lab Biotherapy Zhejiang Prov, Hangzhou 310016, Zhejiang, Peoples R China
[3] Zhejiang Univ, Dept Surg Oncol, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[4] Wenzhou Med Coll, Zhuji Hosp, Dept Surg, Zhuji 311800, Zhejiang, Peoples R China
[5] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Clin Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
angiogenesis; cancer; protease-activated receptors; tumorigenesis; MOLECULAR-WEIGHT HEPARIN; ENDOTHELIAL GROWTH-FACTOR; THROMBIN-INDUCED ANGIOGENESIS; PEPDUCIN-BASED INTERVENTION; HUMAN PLATELET ACTIVATION; TUMOR-SUPPRESSOR PROTEIN; TISSUE FACTOR; IN-VITRO; CELL-PROLIFERATION; ANTIANGIOGENIC AGENTS;
D O I
10.3892/ol.2011.291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The traditional view of the role of proteases in tumor growth, progression and metastasis has significantly changed. Apart from their contribution to cancer progression, it is evident that a subclass of proteases, such as thrombin, serves as signal molecules controlling cell functions through the protease-activated receptors (PARs). Among the four types of PAR (PAR 1-4; cloned and named in order of their discovery), PAR1, PAR3 and PAR4 are activated by thrombin, unlike PAR2, which is activated by trypsin-like serine proteases. Thrombin has been proven to be a significant factor in both the behavior of cancer in its involvement in hemostasis and blood coagulation. Thrombin is a key supporter of various cellular effects relevant to tumor growth and metastasis, as well as a potent activator of angiogenesis, which is essential for the growth and development of all solid tumor types. This review presents an overview of the role of PAR-mediated thrombin in angiogenesis and cancer, focusing on the ability of PAR1- and PAR4-mediated thrombin to affect tumorigenesis and angiogenesis.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 157 条
[61]   Integrin affinity modulation [J].
Hughes, PE ;
Pfaff, M .
TRENDS IN CELL BIOLOGY, 1998, 8 (09) :359-364
[62]   THROMBOSPONDIN EXERTS AN ANTIANGIOGENIC EFFECT ON CORD FORMATION BY ENDOTHELIAL-CELLS INVITRO [J].
IRUELAARISPE, ML ;
BORNSTEIN, P ;
SAGE, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :5026-5030
[63]   Protease-activated receptor 3 is a second thrombin receptor in humans [J].
Ishihara, H ;
Connolly, AJ ;
Zeng, DW ;
Kahn, ML ;
Zheng, YW ;
Timmons, C ;
Tram, T ;
Coughlin, SR .
NATURE, 1997, 386 (6624) :502-506
[64]   Angiogenesis is regulated by a novel mechanism:: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released [J].
Italiano, Joseph E., Jr. ;
Richardson, Jennifer L. ;
Patel-Hett, Sunita ;
Battinelli, Elisabeth ;
Zaslavsky, Alexander ;
Short, Sarah ;
Ryeom, Sandra ;
Folkman, Judah ;
Klement, Giannoula L. .
BLOOD, 2008, 111 (03) :1227-1233
[65]  
Jamieson GA, 1997, THROMB HAEMOSTASIS, V78, P242
[66]   Protease-activated receptor (PAR)-l and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas [J].
Jin, EJ ;
Fujiwara, M ;
Pan, X ;
Ghazizadeh, M ;
Arai, S ;
Ohaki, Y ;
Kajiwara, K ;
Takemura, T ;
Kawanami, O .
CANCER, 2003, 97 (03) :703-713
[67]   Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? [J].
Jin, Ketao ;
Shen, Yanping ;
He, Kuifeng ;
Xu, Zhenzhen ;
Li, Guangliang ;
Teng, Lisong .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (08) :526-532
[68]   Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin [J].
Kahn, ML ;
Nakanishi-Matsui, M ;
Shapiro, MJ ;
Ishihara, H ;
Coughlin, SR .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :879-887
[69]   A dual thrombin receptor system for platelet activation [J].
Kahn, ML ;
Zheng, YW ;
Huang, W ;
Bigornia, V ;
Zeng, DW ;
Moff, S ;
Farese, RV ;
Tam, C ;
Coughlin, SR .
NATURE, 1998, 394 (6694) :690-694
[70]   Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS) [J].
Kakkar, AK ;
Levine, MN ;
Kadziola, Z ;
Lemoine, NR ;
Low, V ;
Patel, HK ;
Rustin, G ;
Thomas, M ;
Quigley, M ;
Williamson, RCN .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1944-1948